Market capitalization | $51.29m |
Enterprise Value | $49.30m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.11 |
P/S ratio (TTM) P/S ratio | 1.15 |
P/B ratio (TTM) P/B ratio | 1.61 |
Sales growth (TTM) Sales growth | 29.85% |
Turnover (TTM) Turnover | $44.50m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
2 Analysts have issued a LENSAR Inc forecast:
2 Analysts have issued a LENSAR Inc forecast:
Mar '24 |
+/-
%
|
||
Net profit | -12 -12 |
30%
30%
|
|
Depreciation and amortization | 3.72 3.72 |
5%
5%
|
|
Share compensation | 4.47 4.47 |
34%
34%
|
|
Operating cash flow | -8.27 -8.27 |
56%
56%
|
|
Investments | 0.25 0.25 |
213%
213%
|
|
Dividend paid | - - |
-
|
|
Free cash flow | -8.52 -8.52 |
55%
55%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.
Head office | United States |
CEO | Nicholas Curtis |
Employees | 130 |
Founded | 2004 |
Website | www.lensar.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.